Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN SODIUM versus PYOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN SODIUM versus PYOPEN.
AMPICILLIN SODIUM vs PYOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
1-2 g IV/IM every 4-6 hours for serious infections; maximum 12 g/day.
4 g intravenously every 4 hours.
None Documented
None Documented
Terminal elimination half-life ~1 hour in healthy adults; prolonged to 2–5 hours in renal impairment (CrCl <10 mL/min) and up to 7–20 hours in anuria; neonatal half-life 2–4 hours.
30-60 minutes in normal renal function; prolonged to 2-4 hours in moderate renal impairment (CrCl 10-30 mL/min) and up to 10 hours in severe renal failure.
Approximately 90% renal excretion via tubular secretion and glomerular filtration; small biliary excretion (<10%); fecal elimination negligible.
Primarily renal (60-90% unchanged via glomerular filtration and tubular secretion); small amounts biliary (10-30%) and fecal (<10%).
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic